These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38502342)

  • 21. Insurance reimbursements for recombinant zoster vaccine in the private sector.
    Leidner AJ; Tang Z; Guo A; Anderson TC; Tsai Y
    Vaccine; 2021 Aug; 39(36):5091-5094. PubMed ID: 34348844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data.
    Lewis CY; Mishra K; Sun Y; Sechrist SJ; Arnold BF; Acharya NR
    Vaccine; 2023 May; 41(23):3493-3496. PubMed ID: 37150621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial.
    Min JY; Mwakingwe-Omari A; Riley M; Molo LY; Soni J; Girard G; Danier J
    J Infect; 2022 Apr; 84(4):490-498. PubMed ID: 34963639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017-2021.
    LaMori J; Feng X; Pericone CD; Mesa-Frias M; Sogbetun O; Kulczycki A
    Vaccine; 2022 Apr; 40(15):2266-2273. PubMed ID: 35292160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survey of Physician Practices, Attitudes, and Knowledge Regarding Recombinant Zoster Vaccine.
    Hurley LP; O'Leary ST; Dooling K; Anderson TC; Crane LA; Cataldi JR; Brtnikova M; Beaty BL; Gorman C; Guo A; Lindley MC; Kempe A
    J Gen Intern Med; 2023 Mar; 38(4):986-993. PubMed ID: 35794307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune-Mediated Inflammatory Diseases in the US.
    Leung J; Anderson TC; Dooling K; Xie F; Curtis JR
    Arthritis Rheumatol; 2022 Nov; 74(11):1833-1841. PubMed ID: 35666070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
    Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
    Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.
    Goud R; Lufkin B; Duffy J; Whitaker B; Wong HL; Liao J; Lo AC; Parulekar S; Agger P; Anderson SA; Wernecke M; MaCurdy TE; Weintraub E; Kelman JA; Forshee RA
    JAMA Intern Med; 2021 Dec; 181(12):1623-1630. PubMed ID: 34724025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.
    Schmid DS; Miao C; Leung J; Johnson M; Weinberg A; Levin MJ
    J Virol; 2021 May; 95(12):. PubMed ID: 33762414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Knowledge, Attitudes and Practices Survey of Recombinant Zoster Vaccine among Cardiologists and Cardiac Nurses in Italy.
    Ponticelli D; Antonazzo IC; Losa L; Zampella A; Di Marino F; Mottola G; Fede MN; Gallucci F; Magliuolo R; Rainone A; Del Giudice C; Arcari A; Ferrara P
    Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256354
    [No Abstract]   [Full Text] [Related]  

  • 31. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer.
    Curran D; Patterson BJ; Carrico J; Salem A; La EM; Lorenc S; Hicks KA; Poston S; Carpenter CF
    Hum Vaccin Immunother; 2023 Dec; 19(1):2167907. PubMed ID: 36880669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older.
    Ackerson B; Qian L; Sy LS; Bruxvoort K; Wu J; Luo Y; Diaz-Decaro J; Talarico C; Tseng HF
    Vaccine; 2021 Feb; 39(6):926-932. PubMed ID: 33441234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
    Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M
    Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial.
    Strezova A; Lal H; Enweonye I; Campora L; Beukelaers P; Segall N; Heineman TC; Schuind AE; Oostvogels L
    Vaccine; 2019 Sep; 37(39):5877-5885. PubMed ID: 31443993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States.
    Florea A; Sy L; Qian L; Ackerson B; Luo Y; Wu J; Cheng Y; Ku J; Vega Daily L; Takhar H; Song J; Chmielewski-Yee E; Spence O; Seifert H; Oraichi D; Tseng HF
    Hum Vaccin Immunother; 2024 Dec; 20(1):2327145. PubMed ID: 38488143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.
    van Oorschot DAM; Hunjan M; Bracke B; Lorenc S; Curran D; Starkie-Camejo H
    BMJ Open; 2019 May; 9(5):e025553. PubMed ID: 31061027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocol.
    Hentzien M; Bonnet F; Bernasconi E; Biver E; Braun DL; Munting A; Leuzinger K; Leleux O; Musardo S; Prendki V; Schmid P; Staehelin C; Stoeckle M; Walti CS; Wittkop L; Appay V; Didierlaurent AM; Calmy A
    BMC Infect Dis; 2024 Mar; 24(1):329. PubMed ID: 38504173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Herpes Virus Infections in Kidney Transplant Patients (HINT) - a prospective observational cohort study.
    Hamm SR; Saini SK; Hald A; Vaaben AV; Pedersen NW; Suarez-Zdunek MA; Harboe ZB; Bruunsgaard H; Johansen IS; Larsen CS; Bistrup C; Birn H; Sørensen SS; Hadrup SR; Nielsen SD
    BMC Infect Dis; 2023 Oct; 23(1):687. PubMed ID: 37845608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis.
    Xia Y; Zhang X; Zhang L; Fu C
    Front Immunol; 2022; 13():978203. PubMed ID: 36248796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.
    Lasagna A; Mele D; Bergami F; Alaimo D; Dauccia C; Alessio N; Comolli G; Pasi F; Muzzi A; Novelli V; Baldanti F; Pedrazzoli P; Cassaniti I
    Hum Vaccin Immunother; 2023 Dec; 19(3):2288282. PubMed ID: 38037900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.